{
    "title": "Individual feed for https://www.marketbeat.com/feed/",
    "link": "https://www.marketbeat.com/feed/",
    "description": "Individual feed output.",
    "lastBuildDate": "2025-10-16T07:12:00.581675",
    "items": [
        {
            "title": "Why Analysts Are Upgrading Ratings After Klarna's IPO",
            "link": "https://www.marketbeat.com/originals/why-analysts-are-upgrading-ratings-after-klarnas-ipo/",
            "description": "Wall Street analysts are drawn to Klarna's strong potential, but the company will face hurdles as it grows its BNPL business and expands its offerings...",
            "pubDate": "2025-10-16T07:08:00",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture7.png"
        },
        {
            "title": "Palantir’s New Healthcare Deal Boosts AI and Data Reach",
            "link": "https://www.marketbeat.com/stock-ideas/palantirs-new-healthcare-deal-boosts-ai-and-data-reach/",
            "description": "Palantir’s new OneMedNet partnership expands its AI and healthcare data footprint, fueling commercial growth and bullish sentiment ahead of earnings",
            "pubDate": "2025-10-15T19:16:00",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture6.png"
        },
        {
            "title": "GM's Billion-Dollar Bruise: GM's Strategic Pivot Makes It a Buy",
            "link": "https://www.marketbeat.com/stock-ideas/gms-billion-dollar-bruise-gms-strategic-pivot-makes-it-a-buy/",
            "description": "General Motors' strategic pivot on its EV plans, backed by a dominant and highly profitable core business, signals a disciplined focus on long-term va...",
            "pubDate": "2025-10-15T18:09:00",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture4.png"
        },
        {
            "title": "Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead",
            "link": "https://www.marketbeat.com/stock-ideas/novo-nordisks-akero-therapeutics-buy-targets-eli-lillys-lead/",
            "description": "Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments",
            "pubDate": "2025-10-15T16:15:00",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture3.png"
        },
        {
            "title": "ASML Can Hit New Highs, But It Won’t Be Easy: Here’s Why",
            "link": "https://www.marketbeat.com/stock-ideas/asml-can-hit-new-highs-but-it-wont-be-easy-heres-why/",
            "description": "ASML is on track to reach record high stock prices, but the move won't come easily as institutional interest is tepid and headwinds remain.",
            "pubDate": "2025-10-15T16:03:00",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture6.png"
        }
    ]
}